Is there a case for screening for quinolone toxicity?
Although screening has been recommended, there is no strong evidence that screening is justified. Screening programmes are costly and may generate needless anxiety and work for clinicians. There is no reliable screening test that will identify reversible toxicity before ophthalmoscopic changes develop and the appearance of age-related macular degeneration may be indistinguishable from toxic damage. Recommendations for good practice in rheumatology and dermatology clinics: baseline assessment • check renal and liver function • ask about visual impairment that is not corrected by spectacles • record near visual acuity of each high using spectacles where appropriate using standard test types If no abnormality is detected, treatment with hydroxychloroquine can be commenced. If visual impairment is present an assessment by an ophthalmologist is advised. maximum day the dosage recommendations Hydroxychloroquine 6.5 mg per kilogram lean body weight (usually 400 mg) daily. If the patient is ov
